Bayer Faces Revenue Decline Amid Ongoing Glyphosate Litigation

The pharmaceutical and agrochemical company Bayer continues to face significant financial and legal challenges, primarily due to ongoing litigation related to the glyphosate-based herbicide, Roundup. Bayer reported a net loss of approximately 3.6 billion euros for the year 2025, representing an increase of around 1.1 billion euros compared to the previous year. This substantial loss is attributed mainly to the costs associated with legal claims against its US subsidiary, Monsanto, over alleged links between glyphosate and cancer.

In response to continued lawsuits, Bayer reached a class-action settlement with claimants in February. As part of this agreement, the company increased its legal provisions by four billion euros, reflecting the anticipated costs of resolving both current and potential future claims. The settlement outlines payments of up to 7.25 billion US dollars (about 6.23 billion euros) over a period of up to 21 years. This arrangement is intended to cover lawsuits in which plaintiffs allege they developed non-Hodgkin lymphoma due to glyphosate exposure.

From an operational standpoint, Bayer experienced a moderate year. Total revenue declined by 2.2 percent, falling to 45.6 billion euros. However, when adjusted for currency fluctuations, the company would have reported a 1.1 percent increase in revenue. The overall financial performance reflects the continued impact of both market conditions and the ongoing legal uncertainties surrounding glyphosate.

Market reactions to these developments have been mixed. Bayer's share price saw an initial upturn in November but declined again after the announcement of the class-action settlement in the United States in mid-February. Investor sentiment remains cautious, as the glyphosate litigation continues to cast a shadow over the company's financial outlook.

The legal process is still underway, with a key court decision expected soon. Following the preliminary approval of the settlement by a court in St. Louis, Missouri, shortly after Bayer's annual press conference, claimants have until early June to either reject the settlement or raise objections. After this period, a court hearing will take place, and a final decision on the settlement's approval will be made.

Bayer regards the preliminary court approval as a critical step forward in resolving the glyphosate litigation. The company hopes that the settlement will help contain its legal risks and bring greater stability to its financial planning. Nevertheless, the resolution remains pending, as the agreement has not yet received final judicial endorsement.

Bayer's acquisition of Monsanto in 2018 brought the glyphosate-related lawsuits into its portfolio, significantly impacting its finances and reputation. The company has since faced thousands of claims in the United States, with plaintiffs asserting that glyphosate exposure is linked to cancer. While Bayer maintains that scientific studies do not conclusively prove such a link, legal proceedings and settlements have resulted in substantial costs and ongoing public scrutiny.

In addition to the financial implications, Bayer continues to promote its pharmaceutical products and innovative agricultural solutions. The company's leadership emphasizes its commitments to health and food security, but the persistent legal disputes present a major challenge to restoring investor confidence and improving its market position.

As the legal process unfolds, the outcome of the settlement and the company's ability to manage remaining and future claims will play a pivotal role in determining Bayer's financial health and strategic direction. Stakeholders will be closely watching for the final court decision and any further developments regarding glyphosate litigation in the months to come.